Видео с ютуба Tarlatamab

Доктор Яннис Маунтзиос | Мелкоклеточный рак легких и мезотелиома: достижения в 2025 году

Game-Changer in Small Cell Lung Cancer? Tarlatamab vs Standard Treatment – DeLLphi-304 Phase 3 Trial

Tarlatamab Mechanism of Action

Tarlatamab: Mechanism of Action and Clinical Success in Small Cell Lung Cancer │ Pharmacology

Evaluating Tarlatamab in Recurrent Small Cell Lung Cancer Treatment

A New Era of Hope for Small Cell Lung Cancer Patients

PROs from DeLLphi-304 evaluating tarlatamab vs chemotherapy in SCLC

Tarlatamab A New Hope for Small Cell Lung Cancer

Тарлатамаб при опухолях, экспрессирующих DLL3, включая нейроэндокринные опухоли • ClinicalTrials....

Updates in SCLC: Tarlatamab and Maintenance - Lung Cancer Key Developments OncPanel 2025-26

Thuốc mới 2026 TARLATAMAB chữa Ung thư phổi tế bào nhỏ

Tarlatamab: The Immunotherapy Beating Chemotherapy in Small Cell Lung Cancer

Side Effects of Tarlatamab and How They Can Be Monitored at Home - 2024 Lung Cancer OncTalk

Exploring tarlatamab in the DeLLphi-301 trial for small cell lung cancer

DeLLphi 304 Tarlatamab in SCLC

Resultados del estudio DeLLphi-301 con tarlatamab en pacientes con CPCP

SCLC Second-Line Treatment: Tarlatamab - Small Cell Lung Cancer OncInsights 2025-26

Tarlatamab in SCLC | DeLLphi-301 Phase 2 Trial Results by Brain Metastasis Status | ASCO 2024

IMDELLTRA (tarlatamab) Hazırlama ve Uygulama Kılavuzu: Adım Adım Rehber

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in 2L SCLC